Innocoll (NASDAQ: INNL) and Sanofi (NYSE:SNY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Earnings & Valuation
This table compares Innocoll and Sanofi’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sanofi||$37.43 billion||3.02||$4.86 billion||$3.92||11.42|
Sanofi has higher revenue and earnings than Innocoll. Innocoll is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
This table compares Innocoll and Sanofi’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Innocoll and Sanofi, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Innocoll presently has a consensus price target of $3.00, indicating a potential upside of 27.66%. Sanofi has a consensus price target of $51.50, indicating a potential upside of 15.01%. Given Innocoll’s stronger consensus rating and higher probable upside, research analysts plainly believe Innocoll is more favorable than Sanofi.
Institutional & Insider Ownership
34.2% of Innocoll shares are held by institutional investors. Comparatively, 9.1% of Sanofi shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.5%. Innocoll does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend. Sanofi has increased its dividend for 2 consecutive years.
Sanofi beats Innocoll on 10 of the 14 factors compared between the two stocks.
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Receive News & Ratings for Innocoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll and related companies with MarketBeat.com's FREE daily email newsletter.